ATTALLA F. EL-KOTT1,2,*, AYMAN E. EL-KENAWY3, EMAN R. ELBEALY4, ALI S. ALSHEHRI1, HEBA S. KHALIFA2, MASHAEL MOHAMMED BIN-MEFERIJ5, EHAB E. MASSOUD6,7,8, AMIRA M. ALRAMLAWY9
BIOCELL, Vol.45, No.5, pp. 1337-1353, 2021, DOI:10.32604/biocell.2021.015464
Abstract This study examined if the anti-tumorigenesis effect of Exendin-4 in HT29 and HCT116 colorectal
cancer (CRC) involves modulation of SIRT1 and Akt/GSR3K/β-catenin/NF-κB axis. HT29 and HCT116 cells were
treated either with increasing levels of Exendin-4 (0.0-200 µM) or with Exendin-4 (at its IC50) in the presence or
absence of EX-527 (10 µM/a selective SIRT1 inhibitor) or Exendin-4 (9-39) amide (E (9-39) A) (1 µM/an Exendin-4
antagonist). In a dose-dependent manner, Exendin-4 inhibited cell survival, but enhanced levels of lactate
dehydrogenase (LDH) and single-stranded DNA (ssDNA) in both HT29 and HCT116. In both cell lines and at it has
an IC50… More >
Login
Register
